Vaccines Europe - 29 Nov 2021
“We understand the concern caused by the emergence of the Omicron variant of COVID-19. Over the last two years the industry has engaged in the biggest collaborative research effort the world has ever seen. Over that time we have built our understanding of how the COVID-19 works and developed the first diagnostics, vaccines and treatments for use in the fight against the disease. Working with the broader scientific community, public health and regulatory bodies around the world, our industry will continue to bring that experience and expertise to bear on new variants such as Omicron.
#WeWontRest in the fight against COVID-19.”
Nathalie Moll, Director General, EFPIA.